Filtered By:
Condition: Heart Disease
Drug: Lipitor

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 659 results found since Jan 2013.

Association of Osteopontin, Neopterin, and Myeloperoxidase With Stroke Risk in Patients With Prior Stroke or Transient Ischemic Attacks Clinical Sciences
Background and Purpose—Established risk factors do not fully identify patients at risk for recurrent stroke. The SPARCL trial (Stroke Prevention by Aggressive Reduction in Cholesterol Levels) evaluated the effect of atorvastatin on stroke risk in patients with a recent stroke or transient ischemic attack and no known coronary heart disease. This analysis explored the relationships between 13 plasma biomarkers assessed at trial enrollment and the occurrence of outcome strokes.Methods—We conducted a case–cohort study of 2176 participants; 562 had outcome strokes and 1614 were selected randomly from those without outcom...
Source: Stroke - November 27, 2017 Category: Neurology Authors: Peter Ganz, Pierre Amarenco, Larry B. Goldstein, Henrik Sillesen, Weihang Bao, Gregory M. Preston, K. Michael A. Welch Tags: Biomarkers, Proteomics, Cerebrovascular Disease/Stroke Original Contributions Source Type: research

Effect of High-Dose Atorvastatin on Renal Function in Subjects With Stroke or Transient Ischemic Attack in the SPARCL Trial Clinical Sciences
Conclusions— This post hoc analysis suggests that atorvastatin treatment may improve renal function in patients with prior stroke or transient ischemic attack with and without chronic kidney disease, and that atorvastatin treatment may prevent eGFR decline in patients with stroke and diabetes mellitus. Clinical Trial Registration— URL: http://www.clinicaltrials.gov. Unique identifier: NCT00147602.
Source: Stroke - September 22, 2014 Category: Neurology Authors: Amarenco, P., Callahan, A., Campese, V. M., Goldstein, L. B., Hennerici, M. G., Messig, M., Sillesen, H., Welch, K. M. A., Wilson, D. J., Zivin, J. A. Tags: Lipids, Secondary prevention, Cerebrovascular disease/stroke Clinical Sciences Source Type: research

Statins in stroke.
Conclusion: Treatment with statins prevents ischemic stroke, especially in patients with high cardiovascular risk and established atherosclerotic disease. It seems that both lipid lowering and pleiotropic effects contribute to these effects. PMID: 31218948 [PubMed - as supplied by publisher]
Source: Current Medicinal Chemistry - June 18, 2019 Category: Chemistry Authors: Aznaouridis K, Masoura C, Vlachopoulos C, Tousoulis D Tags: Curr Med Chem Source Type: research

Low-Density Lipoprotein Cholesterol Level After a Stroke
Randomized clinical trials (RCTs) of statins as the primary prevention for patients with a high serum low-density lipoprotein cholesterol (LDL-C) level and as the secondary prevention after an acute coronary event have shown that lowering serum LDL-C levels reduces the risks of myocardial infarction, stroke, and vascular death. These trials included stroke as a secondary end point but not as an entry criterion. The benefit of LDL-C lowering to reduce the risk of ischemic strokes in primary prevention trials and for patients with coronary heart disease is not necessarily seen among patients who have had a stroke. The Stroke...
Source: JAMA Neurology - February 21, 2022 Category: Neurology Source Type: research

Association between the   TIMD4-HAVCR1 variants and serum lipid levels, coronary heart disease and ischemic stroke risk and atorvastatin lipid-lowering efficacy.
This study aimed to determine the TIMD4-HAVCR1 variants, their haplotypes and gene-environment interactions on serum lipid levels, the risk of CHD and IS, and the lipid-lowering efficacy of atorvastatin in a southern Chinese Han population. Genotypes of 3 variants in 622 controls, 579 CHD and 546 IS patients were determined by the Snapshot technology. Atorvastatin calcium tablet (20 mg/d) was given in 724 hyperlipidemic patients for 8 weeks after genotyping. The rs12522248 genotypic and allelic frequencies were different between controls and patients, and were associated with the risk of CHD and IS. The rs1501908G-rs125222...
Source: Bioscience Reports - December 5, 2017 Category: Biomedical Science Authors: Zhang QH, Yin RX, Chen WX, Cao XL, Chen YM Tags: Biosci Rep Source Type: research

Statins are 'safe, effective and should be used more widely'
Conclusion This study reviews evidence from randomised controlled trials (RCTs) and observational studies to better evaluate the effects and safety of statin therapy. It provides valuable data on the size of the benefits compared with the risks, informing a topic that has had much media coverage in recent times. The researchers highlight that the benefits of statin therapy for people at risk of cardiovascular disease events far outweigh any possible side effects. But it is still for a doctor and their patient to come to a conclusion about what the best treatment for them may be. If you have been prescribed a statin, it...
Source: NHS News Feed - September 9, 2016 Category: Consumer Health News Tags: QA articles Medication Heart/lungs Source Type: news

NICE publishes new draft guidelines on statins use
"Millions more people should be put on cholesterol-lowering statin drugs," BBC News reports. Draft guidance from the National Institute for Health and Care Excellence (NICE) has recommended that the drugs should be given to people with an estimated 1 in 10 or more risk of cardiovascular disease (CVD), which includes conditions such as heart disease and stroke. Statins are medicines that can help lower rates of low-density lipoprotein (LDL) cholesterol (so-called "bad" cholesterol) in the blood. High rates of LDL cholesterol can lead to hardening of the arteries, a risk factor for CVDs. At present,...
Source: NHS News Feed - February 12, 2014 Category: Consumer Health News Tags: Heart/lungs Medication QA articles Source Type: news

'More adults should be taking statins,' says NICE
Conclusion Despite somewhat hysterical media coverage to the contrary ("millions more to be given statins," according to the Daily Express), nobody will be forced to take statins. If your GP does recommend statins, you should ask them to explain the benefits and risks for you personally of starting statin treatment. You may want to find out more about statins before making up your mind – the NHS Choices Health A-Z information on statins is a good place to start. If you do experience troublesome side effects while taking statins, contact your GP or the doctor in charge of your care. It could be the case that a...
Source: NHS News Feed - July 18, 2014 Category: Consumer Health News Tags: Heart/lungs Medication QA articles Source Type: news

Studies support broader use of cholesterol-lowering statins
The latest guidelines used to determine who should take a cholesterol-lowering statin to prevent heart disease appear to be more accurate and cost-efficient than the previous guidelines. That’s according to two studies led by Harvard researchers, both published in this week’s Journal of the American Medical Association. For many years, the main deciding factor in who needed to take a statin was the level of an individual’s harmful low-density lipoprotein cholesterol (LDL). Updated guidelines published in 2013 by the American College of Cardiology and the American Heart Association moved away from LDL and ...
Source: New Harvard Health Information - July 16, 2015 Category: Consumer Health News Authors: Julie Corliss Tags: Drugs and Supplements cholesterol high cholesterol statins Source Type: news

New Studies Give Mixed Results About Taking Fish Oil and Vitamin D
(CHICAGO) — Taking fish oil or vitamin D? Big studies give long-awaited answers on who does and does not benefit from these popular nutrients. Fish oil taken by healthy people, at a dose found in many supplements, showed no clear ability to lower heart or cancer risks. Same for vitamin D. But higher amounts of a purified, prescription fish oil slashed heart problems and heart-related deaths among people with high triglycerides, a type of fat in the blood, and other risks for heart disease. Doctors cheered the results and said they could suggest a new treatment option for hundreds of thousands of patients like these. ...
Source: TIME: Health - November 10, 2018 Category: Consumer Health News Authors: MARILYNN MARCHIONE / AP Tags: Uncategorized onetime Supplements Source Type: news

Impact of High-Dose Atorvastatin Therapy and Clinical Risk Factors on Incident Aortic Valve Stenosis in Patients With Cardiovascular Disease (from TNT, IDEAL, and SPARCL)
Clinical trials have not provided evidence for a role of statin therapy in reducing aortic valve stenosis (AVS) severity in patients with documented AVS. However, whether statin therapy could prevent the onset of AVS is unknown. Our objectives were (1) to compare the incidence rates of AVS among patients treated with high-dose versus usual-dose statin or placebo and (2) to identify clinical risk factors associated with the development of AVS. We conducted post hoc analyses in 23,508 participants from 3 large-scale multicenter atorvastatin randomized blinded clinical trials: Treating to New Targets, the Incremental Decrease...
Source: The American Journal of Cardiology - February 3, 2014 Category: Cardiology Authors: Benoit J. Arsenault, S. Matthijs Boekholdt, Samia Mora, David A. DeMicco, Weihang Bao, Jean-Claude Tardif, Pierre Amarenco, Terje Pedersen, Philip Barter, David D. Waters Tags: Valvular Heart Disease Source Type: research

Why You Should Avoid Statins
At my anti-aging clinic, I continue to wage war against what I call the “medical-industrial complex.” And I do it for one reason only – I care more about my patients than I do about profits. Big Pharma clearly takes the opposite view. And now it seems these pharmaceutical behemoths won’t be happy until every man, woman and child is popping anti-cholesterol pills. Researchers at Duke University recently issued a report recommending that even children and people as young as 30 should be on statins, if they have just slightly elevated cholesterol levels.1 And why wouldn’t researchers at Duke recommen...
Source: Al Sears, MD Natural Remedies - February 3, 2015 Category: Complementary Medicine Authors: Dr. Al Sears Tags: Heart Health Source Type: news

The Jekyll and Hyde of Statins
By Drs. David Niesel and Norbert Herzog, Medical Discovery News Cholesterol-lowering drugs called statins are the most prescribed drug ever. About 30 percent of Americans are currently taking statins such as Crestor, Lipitor, Mevacor and Zocor. Overall, statins can be good thing, but as with all drugs, there are some negative effects. Statins lower cholesterol by inhibiting a protein called HMG-CoA reductase. Since high cholesterol levels are linked to heart disease, statins can reduce the risks of heart attack and stroke, two of the leading causes of death in the United States. Recent reports from the American Heart Assoc...
Source: Science - The Huffington Post - February 3, 2016 Category: Science Source Type: news

Cardiovascular Event Reduction Versus New-Onset Diabetes During Atorvastatin Therapy Effect of Baseline Risk Factors for Diabetes
ConclusionsCompared with lower-dose statin therapy, atorvastatin 80 mg/day did not increase the incidence of NOD in patients with 0 to 1 NOD risk factors but did, by 24%, among patients with 2 to 4 NOD risk factors. The number of CV events was significantly reduced with atorvastatin 80 mg in both NOD risk groups.
Source: Journal of the American College of Cardiology: Cardiovascular Interventions - January 7, 2013 Category: Cardiology Source Type: research

The Inhibitory Effect of Simvastatin and Aspirin on Histamine Responsiveness in Human Vascular Endothelial Cells.
Abstract Statins and aspirin deliver well-established cardiovascular benefits resulting in their increased use as combined polypills to decrease risk of stroke and heart disease. However, the direct endothelial effect of combined statin/aspirin cotreatment remains unclear. Histamine is an inflammatory mediator that increases vascular permeability and so we examined the effect of treating human umbilical vein endothelial cells (HUVECs) for 24-hours with 1μM simvastatin and 100μM aspirin on histamine responsiveness. Subsequent histamine (1μM) challenge increased Ca(2+)i concentration, an effect that was significa...
Source: Am J Physiol Cell Ph... - January 29, 2014 Category: Cytology Authors: Absi M, Bruce JI, Ward DT Tags: Am J Physiol Cell Physiol Source Type: research